Xencor, Inc.

NASDAQ:XNCR

Biotechnology

Healthcare
$34.39 -1.03%

-$0.13 today

Market cap
$2.58B
Beta
0.93
P/E (TTM)
-5.5
EPS (TTM)
-$2.29
52W Low $6.92High $18.69

Volume 0.87M

Average 0.80M

XNCR Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Xencor, Inc.NASDAQ: XNCR

Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026

Depreciation & amortization declines year over year

Q2 FY2026 depreciation & amortization of $2.44M fell 8.0% year over year, ahead of the -10.7% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 4.9% from the prior quarter. Over 3 fiscal years it compounded at +6.1% a year.

Context

  • Depreciation & amortization amounted to 8.4% of revenue in FY2025, down 2.6 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -8.0% holds above the trailing-twelve-month pace of -10.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$2.44M-4.9% QoQ
Last fiscal yearDec 2025
$10.51M-13.2% YoY
LTMJun 2026
$10.17M-10.7% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-8.0%——
1 year-13.2%——
3-year CAGR+6.1%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
10.51M USD
Year-over-year change
-13.2%
4-year CAGR
+8.8%

Depreciation & Amortization vs competitors

How XNCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -10.7% is the 5th highest of 8, against a peer median of -7.1%.
  • Depreciation & amortization amounts to 9.7% of revenue for XNCR, versus a peer median of 3.3%.
XNCR Competitors
Depreciation & Amortization for XNCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GMABGenmab A/SLTM Jun 2026$44M USD—-41.9%1.1%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$15.87M USD-14.3%+20.4%2.3%
XNCRXencor, Inc.LTM Jun 2026$10.17M USD-10.7%+6.1%9.7%
MGNXMacroGenics, Inc.LTM Mar 2026$6.94M USD-7.1%-22.5%4.4%
IPHAInnate Pharma S.A.FY2025€5.09M EUR+155.3%-51.8%182.7%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$3.73M USD+10.4%+5.3%3333.9%
IMCRImmunocore Holdings plcLTM Mar 2026$3.36M USD-17.0%-23.1%0.9%
IMMPImmutep LimitedFY2025A$2.39M AUD+5.6%+5.0%47.4%
ADAGAdagene Inc.LTM Jun 2024$515.94K USD—-25.9%63.2%
NKTRNektar TherapeuticsLTM Jun 2026$129K USD-88.2%—0.2%
CGENCompugen Ltd.LTM Dec 2025$0 USD—-0.5%0.0%
Peer median (excluding XNCR) —-7.1%-22.5%3.3%

Competitors are the stored peer set for XNCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income82.63M(55.18M)(133.13M)(236.54M)(91.92M)
Depreciation & Amortization7.49M8.8M11.5M12.11M10.51M
Deferred Income Tax(18.97M)0000
Stock-Based Compensation36.98M48.91M053.28M43.23M
Change in Working Capital(102.6M)48.87M19.13M(40.4M)47.45M
Accounts Receivables(54.94M)36.86M19.83M(32.67M)28.73M
Inventory1.4M0000
Accounts Payables5.05M(3.91M)3.83M2.85M(3.95M)
Other Working Capital(54.11M)15.92M(4.53M)(10.57M)22.67M
Other Non-Cash Items(22.38M)(26.91M)24.58M9.36M(144.39M)
Operating Cash Flow(16.85M)24.49M(77.93M)(202.19M)(135.12M)
Capital Expenditures(15.98M)(43.4M)(18.45M)(6.1M)(3.15M)
Acquisitions (Net)(2.66M)0501K00
Purchases of Investments(509.6M)(387.93M)(782.91M)(595.05M)(298.9M)
Sales of Investments485.15M306.61M693.09M596.66M427.64M
Other Investing Activities(3.16M)90K0(3.38M)14.39M
Investing Cash Flow(46.25M)(119.73M)(110.57M)(7.87M)139.99M
Debt Repayment00000
Common Stock Issued28.92M05.39M201.26M9.96M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities14.12M5.7M183.33M(4.1M)(1.73M)
Financing Cash Flow43.04M5.7M188.72M197.15M8.23M
Effect of Forex Changes00(380K)00
Net Change in Cash(20.06M)(89.54M)(152K)(12.91M)13.1M
Free Cash Flow(32.83M)(18.92M)(96.37M)(208.29M)(138.27M)

Xencor, Inc.

NASDAQ:XNCR

Intrinsic Alpha fair value

Locked

Current Price

$34.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.